Biological
OMS721
OMS721 is a biological therapy with 3 clinical trials. Historical success rate of 50.0%.
Total Trials
3
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 1 completed trials
Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
200%(2 trials)
Terminated
1(33%)
Phase Distribution
Ph phase_3
1
33%
Ph phase_2
1
33%
Phase Distribution
0
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
Phase 3Large-scale testing
1(50.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(1)
Terminated(1)
Other(1)
Detailed Status
Completed1
Terminated1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
50.0%
Most Advanced
Phase 3
Trials by Phase
Phase 21 (50.0%)
Phase 31 (50.0%)
Trials by Status
completed133%
terminated133%
unknown133%
Recent Activity
0 active trials
Showing 3 of 3
terminatedphase_3
Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy
NCT03608033
completedphase_2
Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies
NCT02222545
unknown
OMS721 Compassionate Use in Patients With Thrombotic Microangiopathy
NCT02355782
Clinical Trials (3)
Showing 3 of 3 trials
NCT03608033Phase 3
Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy
NCT02222545Phase 2
Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies
NCT02355782
OMS721 Compassionate Use in Patients With Thrombotic Microangiopathy
All 3 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 3